Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14273065 | 0.84 | L3MBTL1 (0.56) | L3MBTL1GLAPOLBSMN1; SMN2KDM4E | |
| SCHEMBL3029800 | 0.84 | HCRTR1 (0.62) | L3MBTL1GLAKDM4EABCB1ALDH1A1 | |
| SCHEMBL3618678 | 0.83 | ALDH1A1 (0.56) | SMN1; SMN2KDM4EABCB1ALDH1A1HTT | |
| SCHEMBL16036357 | 0.83 | L3MBTL1 (0.54) | L3MBTL1GLAPOLBSMN1; SMN2KDM4E | |
| SCHEMBL4006491 | 0.82 | LMNA (0.64) | L3MBTL1GLAPOLBSMN1; SMN2KDM4E | |
| SCHEMBL18702668 | 0.82 | ABCB1 (0.71) | SMN1; SMN2ABCB1ALDH1A1HPGDRAB9A | |
| SCHEMBL29502958 | 0.82 | KDM4E (0.73) | L3MBTL1GLAPOLBSMN1; SMN2KDM4E | |
| SCHEMBL341639 | 0.82 | KDM4E (0.73) | L3MBTL1GLAPOLBSMN1; SMN2KDM4E | |
| SCHEMBL8414408 | 0.82 | L3MBTL1 (0.61) | L3MBTL1GLAPOLBSMN1; SMN2KDM4E | |
| SCHEMBL4431127 | 0.81 | SGMS2 (0.59) | L3MBTL1POLBSMN1; SMN2KDM4EABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220227739-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS INC (US) | 2022-07-21 | — | — | US | disclosed |
| CN-108430994-B | Compounds, compositions and methods for modulating CFTR | 蛋白质平衡治疗股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-11136313-B2 | Compounds, compositions, and methods for modulating CFTR | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| EP-3359536-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20200385365-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-10550106-B2 | Compounds, compositions, and methods for modulating CFTR | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20180291006-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS, INC. | 2018-10-11 | — | — | US | disclosed |
| WO-2017062581-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-04-13 | — | — | WO | disclosed |
| CN-1314906-A | Salts of paroxetine | SMITHKLINE BEECHAM PLC (GB) | 2001-09-26 | — | — | CN | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| US-4207234-A | 4-Unsubstituted azetidinone derivatives and process for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136313-B2 | Compounds, compositions, and methods for modulating CFTR | CFTR, SCNN1B, SCNN1G | L3MBTL1 3020/4885GLA 3259/4885POLB 1071/4885 |
| US-20200385365-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | CFTR, SCNN1B, SCNN1G | L3MBTL1 3020/4885GLA 3259/4885POLB 1071/4885 |
| US-20220227739-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | CFTR, SCNN1B, SCNN1G | L3MBTL1 3020/4885GLA 3259/4885POLB 1071/4885 |
| US-10550106-B2 | Compounds, compositions, and methods for modulating CFTR | CFTR, SCNN1B, SCNN1G | L3MBTL1 3020/4885GLA 3259/4885POLB 1071/4885 |
| US-20180291006-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | CFTR, SCNN1B, SCNN1G | L3MBTL1 3020/4885GLA 3259/4885POLB 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.